David R. Newell

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

A. Hilary Calvert, David R. Newell, Lindsey Gumbrell et al. · Journal of Clinical Oncology · 1989 · 1.9K citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

A. Hilary Calvert, S.J. Harland, David R. Newell et al. · Cancer Chemotherapy and Pharmacology · 1982 · 486 citations

Medicine, Medicinal Chemistry, Pharmacology +5

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Christopher Calabrese, Robert J. Almassy, Stephen Barton et al. · JNCI Journal of the National Cancer Institute · 2004 · 485 citations · Full text

Medicine, Oncology, Pharmacology +15

Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441

Yan Zhao, Huw D. Thomas, Michael A. Batey et al. · Cancer Research · 2006 · 447 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ruth Plummer, Christopher J. Jones, Mark R. Middleton et al. · Clinical Cancer Research · 2008 · 384 citations · Full text

Medicine, Oncology, Pharmacology +15